COVID-19 is bad news for new drug launches. Which will suffer most?

3rd April 2020 Uncategorised 0

Amid the COVID-19 pandemic new drug rollouts, especially for chronic diseases, face an uphill fight, analysts figure. Bristol Myers has already postponed a big new rollout, and Novartis, Gilead Sciences and Roche could see their closely watched prospects held up by regulatory delays.

More: COVID-19 is bad news for new drug launches. Which will suffer most?
Source: fierce